Phase 2 Vitiligo Trial, Recruiting NCT07223229 Sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd. Condition: Vitiligo
Back to Vitiligo

Phase 2 Vitiligo Trial, Recruiting

NCT07223229
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to read, understand, and sign a consent form agreeing to take part in the study.
  • You are a man or woman between 18 and 65 years old at the time of signing consent.
  • Your body weight is at least 40 kg (about 88 lbs) and your body mass index (a measure of weight relative to height) falls between 18 and 38.
  • You have been diagnosed with a specific type of vitiligo called non-segmental vitiligo for at least 3 months.
  • Your vitiligo has not responded well enough to previous treatments (such as creams, light therapy, or oral medicines used for at least 3–6 months), or you are unable to use those treatments because they are not suitable or caused problems for you.
  • The amount of skin affected by vitiligo on your face and body meets certain minimum levels measured by standard scoring tools used by doctors (confirm with trial site for exact measurements).
  • You are willing to stop all current vitiligo treatments from the start of the study until the very end.
  • If you have never been vaccinated against shingles (herpes zoster), you agree to complete that vaccination before the study begins.
  • If you are a woman who could become pregnant, you agree to use an approved method of contraception during the study (confirm with trial site for specific requirements).

Who may not be able to join:

  • You have a different type of vitiligo (such as segmental vitiligo) or another skin condition that causes loss of skin colour (confirm with trial site for the full list of conditions).
  • More than 30% of the hair on your face or body has turned white or lost colour.
  • You have certain mental health concerns that may affect safe participation (confirm with trial site).
  • You have recently used certain vitiligo treatments, including surgical procedures or specific skin-lightening agents (confirm with trial site for timeframes).
  • You have recently used high doses of steroid medicines (confirm with trial site).
  • You are currently pregnant or breastfeeding.
  • You have certain other medical conditions that the study doctors consider would make participation unsafe (confirm with trial site).
  • You have previously used certain medicines or therapies that are not allowed in this study (confirm with trial site).
  • You have certain heart problems or abnormal heart test results.
  • You have an abnormal chest X-ray result.
  • You have reduced kidney function.
  • Your blood or other laboratory test results at the start of the study are significantly abnormal, based on the doctor's judgement.
  • You have certain active viral infections (confirm with trial site for specifics).
  • You have a known allergy or have had a severe reaction to the study drug (EI-001) or any of its ingredients.
  • You have any condition that might make it difficult for you to follow the study schedule, attend appointments, or safely take part in the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Registry
ClinicalTrials.gov
Start date
30 December 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇹🇼 Taiwan 🇺🇸 United States

Primary endpoints

Percent change in F-VASI from baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov